Latent Cognitive Profiles Differ Between Incipient Alzheimer’s Disease and Dementia with Subcortical Vascular Lesions in a Memory Clinic Population

2020 ◽  
Vol 73 (3) ◽  
pp. 955-966
Author(s):  
Mattias Göthlin ◽  
Marie Eckerström ◽  
Magnus Lindwall ◽  
Sindre Rolstad ◽  
Carl Eckerström ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Lesions ◽  
Cognitive Profiles ◽  
Memory Clinic ◽  
Clinic Population

P1-371: New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population

2008 ◽  
Vol 4 ◽  
pp. T327-T328 ◽  
Author(s):  
Femke H. Bouwman ◽  
Nicolaas A. Verwey ◽  
Martin Klein ◽  
Yolande A.L. Pijnenburg ◽  
Astrid Kok ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Clinic ◽  
New Research ◽  
Research Criteria ◽  
Clinic Population

Neuropsychological performance in Alzheimer's disease and vascular dementia: comparisons in a memory clinic population

2003 ◽  
Vol 18 (7) ◽  
pp. 602-608 ◽  
Author(s):  
Sarah Baillon ◽  
Saquib Muhommad ◽  
Mangesh Marudkar ◽  
Srinivas Suribhatla ◽  
Michael Dennis ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Neuropsychological Performance ◽  
Memory Clinic ◽  
Clinic Population

scholarly journals Cerebrospinal fluid and saliva lactoferrin as a diagnostic biomarker for Alzheimer’s disease in a mixed memory clinic population

2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Helena Sophia Gleerup ◽  
Camilla Steen Jensen ◽  
Peter Høgh ◽  
Steen Gregers Hasselbalch ◽  
Anja Hviid Simonsen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Diagnostic Biomarker ◽  
Memory Clinic ◽  
Clinic Population

scholarly journals Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population

2017 ◽  
Vol 27 (8) ◽  
pp. 3147-3155 ◽  
Author(s):  
Jules J. Claus ◽  
Salka S. Staekenborg ◽  
Dana C. Holl ◽  
Jelmen J. Roorda ◽  
Jacqueline Schuur ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Temporal Lobe ◽  
Medial Temporal Lobe ◽  
Memory Clinic ◽  
Medial Temporal Lobe Atrophy ◽  
Large Memory ◽  
Clinic Population ◽  
Lobe Atrophy

Neuropsychological performance in early and late onset Alzheimer's disease: comparisons in a memory clinic population

2004 ◽  
Vol 19 (12) ◽  
pp. 1140-1147 ◽  
Author(s):  
Srinivas Suribhatla ◽  
Sarah Baillon ◽  
Michael Dennis ◽  
Mangesh Marudkar ◽  
Saquib Muhammad ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Late Onset ◽  
Neuropsychological Performance ◽  
Memory Clinic ◽  
Clinic Population

New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population

2010 ◽  
Vol 30 (1) ◽  
pp. 1-7 ◽  
Author(s):  
F.H. Bouwman ◽  
N.A. Verwey ◽  
M. Klein ◽  
A. Kok ◽  
M.A. Blankenstein ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Memory Clinic ◽  
New Research ◽  
Research Criteria ◽  
Clinic Population

scholarly journals Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population

EBioMedicine ◽  
2021 ◽  
Vol 67 ◽  
pp. 103361
Author(s):  
Helena Sophia Gleerup ◽  
Camilla Steen Jensen ◽  
Peter Høgh ◽  
Steen Gregers Hasselbalch ◽  
Anja Hviid Simonsen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Diagnostic Biomarker ◽  
Memory Clinic ◽  
Clinic Population

EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer’s Disease

2011 ◽  
Vol 31 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Lieke L. Smits ◽  
Maarten Liedorp ◽  
Teddy Koene ◽  
Ilona E.W. Roos-Reuling ◽  
Afina W. Lemstra ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Profiles ◽  
Eeg Abnormalities

scholarly journals Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer’s Disease and Other Dementias

2020 ◽  
pp. 1-14
Author(s):  
Yi-Wen Bao ◽  
Anson C.M. Chau ◽  
Patrick Ka-Chun Chiu ◽  
Yat Fung Shea ◽  
Joseph S.K. Kwan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Amyloid Β ◽  
Standardized Uptake Value ◽  
Subjective Cognitive Decline ◽  
Cognitively Impaired ◽  
Memory Clinic ◽  
Pet Ct

Background: With the more widespread use of 18F-radioligand-based amyloid-β (Aβ) PET-CT imaging, we evaluated Aβ binding and the utility of neocortical 18F-Flutemetamol standardized uptake value ratio (SUVR) as a biomarker. Objective: 18F-Flutemetamol SUVR was used to differentiate 1) mild cognitive impairment (MCI) from Alzheimer’s disease (AD), and 2) MCI from other non-AD dementias (OD). Methods: 109 patients consecutively recruited from a University memory clinic underwent clinical evaluation, neuropsychological test, MRI and 18F-Flutemetamol PET-CT. The diagnosis was made by consensus of a panel consisting of 1 neuroradiologist and 2 geriatricians. The final cohort included 13 subjective cognitive decline (SCD), 22 AD, 39 MCI, and 35 OD. Quantitative analysis of 16 region-of-interests made by Cortex ID software (GE Healthcare). Results: The global mean 18F-Flutemetamol SUVR in SCD, MCI, AD, and OD were 0.50 (SD-0.08), 0.53 (SD-0.16), 0.76 (SD-0.10), and 0.56 (SD-0.16), respectively, with SUVR in SCD and MCI and OD being significantly lower than AD. Aβ binding in SCD, MCI, and OD was heterogeneous, being 23%, 38.5%, and 42.9% respectively, as compared to 100% amyloid positivity in AD. Using global SUVR, ROC analysis showed AUC of 0.868 and 0.588 in differentiating MCI from AD and MCI from OD respectively. Conclusion: 18F-Flutemetamol SUVR differentiated MCI from AD with high efficacy (high negative predictive value), but much lower efficacy from OD. The major benefit of the test was to differentiate cognitively impaired patients (either SCD, MCI, or OD) without AD-related-amyloid-pathology from AD in the clinical setting, which was under-emphasized in the current guidelines proposed by Amyloid Imaging Task Force.

Sign in / Sign up

Export Citation Format

Share Document